123 Main Street, New York, NY 10001

Contact details:

Contact Person: Roos Verhofstad
E-mail: [email protected]
Phone Number: +31 20 8097910
Website: CRO & Biopharmaceutical Services | Parexel
Company LinkedIn Page: https://www.linkedin.com/company/parexel


At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™
When clinical research is easy for patients to participate in, clinical trial timelines move faster, and your revolutionary science gets to patients more quickly. Parexel constantly enhances trial designs and operations to be more inclusive while delivering faster start-up and completion. Our trials framework integrates the latest advances from the global innovation community. Regulatory and access experts are a part of your team from day one, so each step is planned to deliver the evidence you’ll need to succeed. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough.

The integration of clinical excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more.

At Parexel, your patients inspire us to deliver better trials faster than ever. How do we achieve these results? We leverage one of our strengths, operational excellence to deliver With Heart.
We apply clinical and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical leaders and emerging innovators to build trials that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers the best solutions to make every phase of trials more efficient. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With Heart to treat patients with dignity and learn from their experiences, so every trial makes a difference.

In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Durham, North Carolina, and employ 20,760 professionals in more than 100 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners. Parexel was named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards in November 2023. Because working together, and caring deeply, is how we achieve incredible outcomes! Parexel was recognized for the second consecutive year in 2023 as “Top CRO to Work With” in the WCG CenterWatchGlobal Site Relationship Benchmark survey and has received a silver rating for the last two years by Ecovadis, an independent and trusted business sustainability organization. Parexel was also named the 2022 Catalyst Award Winner for our commitment to diversity, equality, and inclusion. For three consecutive years, Parexel has been a top scorer in the corporate equality index, which is a premier survey benchmarking tool that measures how global corporations are adopting equitable workplace policies, practices and benefits for LGBTQ+ employees.